Robert Gieseler

Biologist by training; received his PhD in Immunology in 1991. When at Georg August University in Göttingen, he was among those elucidating the ontogeny of myeloid dendritic cells, and he co-developed the gold standard in-vitro differentiation protocol for these APCs. From 1989 to 1990, he worked with Scolaro in a joint HIV/AIDS research program by St. Vincent Medical Center and the University of Southern California Medical School in Los Angeles, USA. Subsequently, he did commissioned work for the Merck Frosst Centre for Therapeutic Research in Quebec, Canada, and then led preclinical research programs on solid organ transplantation, oncology, and autoimmunity at Georg August University, Göttingen, and the University of Essen Medical School in Essen, Germany. As of 2001, Gieseler worked for five years as Chief Scientist at a public non-profit research institute in Los Angeles together with Scolaro. With a team of scientists, their work provided the foundation for the proprietary technology developed at RBT; in parallel, he held a position as Adjunct Professor at the University of Florida, USA. Subsequently, he supervised the Northern Europe R&D division of Laboratorios LETI, S.L., Spain. As of 2007, he has been appointed as Research Coordinator on hepatitis C and other liver diseases at the University of Essen Medical School.